Market revenue in 2023 | USD 2,049.0 million |
Market revenue in 2030 | USD 3,540.5 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 84.76% in 2023. Horizon Databook has segmented the U.S. hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for hereditary testing, owing to easy access to newborn screening in this country. Newborn screening is one of the most successful public health programs in the U.S. According to Centers for Disease Control and Prevention (CDC), more than 4 million infants are screened, and thousands are treated early for disability and death every year in the U.S.
The participation rate of the U.S. population in newborn screening is around 95%. Early detection & diagnosis of disorders in newborns significantly improves the chances of healthy development and positive outcomes. However, overall growth in newborn screening is expected to decrease in the U.S. as compared to other countries, due to declining birthrate.
In 2018, there were 3,788,235 births, which represents a 2% decline in birthrate from 2017. Moreover, total fertility rate declined to 1,728 births per 1,000 women over their lifetimes, which represented a 2% decline from 2017.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into U.S. hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account